Live Breaking News & Updates on Mankind Pharma Stock Update
Stay updated with breaking news from Mankind pharma stock update. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Mankind Pharma Q3: Domestic revenue grew 20% YoY to Rs 2,400 crore, while exports more than doubled to Rs 207 crore. The strong domestic revenue was led by robust growth in the chronic portfolio, recovery in anti-infectives and strong growth in modern trade and hospital sales. ....
Mankind Pharma is majority-owned by promoters at 76.5% stake, while the public owns the remaining 23.5%. Among the public shareholders, mutual funds own 3.9%, while foreign investors have another 3.9%. Shares of the company delivered 30% returns over a 12-month period, outperforming the Nifty Index, which has given nearly 13% returns during this time. ....
Kotak Mahindra Capital is one of the advisors to the deal, and the private equity investors are offering a discount of upto 7% from the current price. The floor price has been set at Rs 1,785.65 a share. ....
Sectorally, buying was seen in IT, telecom, healthcare and public sector stocks while selling was seen in auto, utilities, capital goods, and FMCG stocks. ....
Operating profit, calculated as earnings before interest, taxes, depreciation and amortisation (EBITDA) for the quarter surged 43% YoY to Rs 660 crore, with margins expanding by a staggering 450 basis points to 25.6%. ....